Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy

D. Heather Watts, Deborah L. Covington, Karen Beckerman, Patricia Garcia, Angela Scheuerle, Kenneth Dominguez, Brenda Ross, Susan Sacks, Scott Chavers, Hugh Tilson

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The purpose of this study was to examine teratogenic risk of antiretroviral (ARV) drugs. The Antiretroviral Pregnancy Registry (APR) monitors prenatal exposures to ARV drugs and pregnancy outcome through a prospective exposure-registration cohort. Statistical inference uses exact methods for binomial proportions. Through July 2003, APR has monitored 3583 live births exposed to ARV. Among 1391 first trimester exposures, there were 38 birth defects, prevalence of 2.7% (95% CI 1.9-3.7), not significantly higher than the CDC's population surveillance rate, 3.1 per 100 live births (95% CI 3.1-3.2). For lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine, sufficient numbers of live births (>200) following first-trimester exposures have been monitored to allow detection of a 2-fold increase in risk of birth defects overall; no increases have been detected. APR data demonstrate no increase in prevalence of birth defects overall or among women exposed to lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine.

Original languageEnglish (US)
Pages (from-to)985-992
Number of pages8
JournalAmerican Journal of Obstetrics and Gynecology
Volume191
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Live Birth
Nelfinavir
Registries
Zidovudine
First Pregnancy Trimester
Pregnancy
Population Surveillance
Stavudine
Nevirapine
Lamivudine
Pregnancy Outcome
Centers for Disease Control and Prevention (U.S.)
Pharmaceutical Preparations

Keywords

  • Anti-retroviral therapy
  • Birth Defects
  • HIV
  • Pregnancy

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. / Heather Watts, D.; Covington, Deborah L.; Beckerman, Karen; Garcia, Patricia; Scheuerle, Angela; Dominguez, Kenneth; Ross, Brenda; Sacks, Susan; Chavers, Scott; Tilson, Hugh.

In: American Journal of Obstetrics and Gynecology, Vol. 191, No. 3, 09.2004, p. 985-992.

Research output: Contribution to journalArticle

Heather Watts, D, Covington, DL, Beckerman, K, Garcia, P, Scheuerle, A, Dominguez, K, Ross, B, Sacks, S, Chavers, S & Tilson, H 2004, 'Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy', American Journal of Obstetrics and Gynecology, vol. 191, no. 3, pp. 985-992. https://doi.org/10.1016/j.ajog.2004.05.061
Heather Watts, D. ; Covington, Deborah L. ; Beckerman, Karen ; Garcia, Patricia ; Scheuerle, Angela ; Dominguez, Kenneth ; Ross, Brenda ; Sacks, Susan ; Chavers, Scott ; Tilson, Hugh. / Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. In: American Journal of Obstetrics and Gynecology. 2004 ; Vol. 191, No. 3. pp. 985-992.
@article{d85ffd653d754807af089624652d09a9,
title = "Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy",
abstract = "The purpose of this study was to examine teratogenic risk of antiretroviral (ARV) drugs. The Antiretroviral Pregnancy Registry (APR) monitors prenatal exposures to ARV drugs and pregnancy outcome through a prospective exposure-registration cohort. Statistical inference uses exact methods for binomial proportions. Through July 2003, APR has monitored 3583 live births exposed to ARV. Among 1391 first trimester exposures, there were 38 birth defects, prevalence of 2.7{\%} (95{\%} CI 1.9-3.7), not significantly higher than the CDC's population surveillance rate, 3.1 per 100 live births (95{\%} CI 3.1-3.2). For lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine, sufficient numbers of live births (>200) following first-trimester exposures have been monitored to allow detection of a 2-fold increase in risk of birth defects overall; no increases have been detected. APR data demonstrate no increase in prevalence of birth defects overall or among women exposed to lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine.",
keywords = "Anti-retroviral therapy, Birth Defects, HIV, Pregnancy",
author = "{Heather Watts}, D. and Covington, {Deborah L.} and Karen Beckerman and Patricia Garcia and Angela Scheuerle and Kenneth Dominguez and Brenda Ross and Susan Sacks and Scott Chavers and Hugh Tilson",
year = "2004",
month = "9",
doi = "10.1016/j.ajog.2004.05.061",
language = "English (US)",
volume = "191",
pages = "985--992",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy

AU - Heather Watts, D.

AU - Covington, Deborah L.

AU - Beckerman, Karen

AU - Garcia, Patricia

AU - Scheuerle, Angela

AU - Dominguez, Kenneth

AU - Ross, Brenda

AU - Sacks, Susan

AU - Chavers, Scott

AU - Tilson, Hugh

PY - 2004/9

Y1 - 2004/9

N2 - The purpose of this study was to examine teratogenic risk of antiretroviral (ARV) drugs. The Antiretroviral Pregnancy Registry (APR) monitors prenatal exposures to ARV drugs and pregnancy outcome through a prospective exposure-registration cohort. Statistical inference uses exact methods for binomial proportions. Through July 2003, APR has monitored 3583 live births exposed to ARV. Among 1391 first trimester exposures, there were 38 birth defects, prevalence of 2.7% (95% CI 1.9-3.7), not significantly higher than the CDC's population surveillance rate, 3.1 per 100 live births (95% CI 3.1-3.2). For lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine, sufficient numbers of live births (>200) following first-trimester exposures have been monitored to allow detection of a 2-fold increase in risk of birth defects overall; no increases have been detected. APR data demonstrate no increase in prevalence of birth defects overall or among women exposed to lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine.

AB - The purpose of this study was to examine teratogenic risk of antiretroviral (ARV) drugs. The Antiretroviral Pregnancy Registry (APR) monitors prenatal exposures to ARV drugs and pregnancy outcome through a prospective exposure-registration cohort. Statistical inference uses exact methods for binomial proportions. Through July 2003, APR has monitored 3583 live births exposed to ARV. Among 1391 first trimester exposures, there were 38 birth defects, prevalence of 2.7% (95% CI 1.9-3.7), not significantly higher than the CDC's population surveillance rate, 3.1 per 100 live births (95% CI 3.1-3.2). For lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine, sufficient numbers of live births (>200) following first-trimester exposures have been monitored to allow detection of a 2-fold increase in risk of birth defects overall; no increases have been detected. APR data demonstrate no increase in prevalence of birth defects overall or among women exposed to lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine.

KW - Anti-retroviral therapy

KW - Birth Defects

KW - HIV

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=4644291083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644291083&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2004.05.061

DO - 10.1016/j.ajog.2004.05.061

M3 - Article

C2 - 15467577

AN - SCOPUS:4644291083

VL - 191

SP - 985

EP - 992

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -